Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma

Cancer Gene Therapy

Volumn 20, Issue 9, 2013, Pages 499-506

  Pezuk, J A ^a   Brassesco, M S ^a   Morales, A G ^a   De Oliveira, J C ^a   De Paula Queiroz, R G ^a   MacHado, H R ^a   Carlotti, C G ^a   Neder, L ^a   Scrideli, C A ^a   Tone, L G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cell cycle; glioblastoma; PLK1 inhibition; Polo like kinases

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; GSK 461364; GW 843682X; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; POLO LIKE KINASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VOLASERTIB;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MITOSIS INDEX; PRIMARY CULTURE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR STEM CELL ASSAY;

EID: 84884594776     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.46     Document Type: Article

References (52)

1. Yang S, Liu J, Wang T, Li X, You C. Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution. Int J Neurosci 2013. doi:10.3109/00207454.2013.791292.
2. Khalatbari MR, Hamidi M, Moharamzad Y. Glioblastoma multiforme with very rapid growth and long-term survival in children: report of two cases and review of the literature. Childs Nerv Syst 2011; 27: 1347-1352.
3. Slotty PJ, Siantidis B, Beez T, Steiger HJ, Sabel M. The impact of improved treatment strategies on overall survival in glioblastoma patients. Acta Neurochir (Wien) 2013; 155: 959-963.
4. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol 2008; 67: 139-152.
5. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-660.
6. Bruinsma W, Raaijmakers JA, Rh Medema. Switching Polo-like kinase-1 on and off in time and space. Trends Biochem Sci 2012; 37: 534-542.
7. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005; 24: 260-266. (Pubitemid 40188606)
8. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010; 19: 27-43.
9. Sanhaji M, Louwen F, Zimmer B, Kreis NN, Roth S, Yuan J. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle 2013; 12: 1340-1351.
10. Garuti L, Roberti M, Bottegoni G. Polo-like kinases inhibitorsCurr Med Chem 2012; 19: 3937-3948.
11. Johnson EE, Stewart KD, Woods KW, Giranda VL, Luo Y. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 2007; 46: 9551-9563. (Pubitemid 47291962)
12. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS et al. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells 2011; 32: 209-220.
13. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322. (Pubitemid 46241881)
14. Valente V, Teixeira SA, Neder L, Okamoto OK, Oba-Shinjo SM, Marie SK et al. Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 2009; 10: 17.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCt method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
16. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-2319.
17. Chou TC, Talalay O. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
18. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2012; 12: 26-33.
19. Stupp R, Newlands E. New approaches for temozolomide therapy: use in newly diagnosed glioma. Semin Oncol 2001; 28: 19-23. (Pubitemid 32879942)
20. Dietzmann K, Kirches E, von Bossanyi K, Jachau K, Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001; 53: 1-11. (Pubitemid 32936653)
21. Wasch R, Hasskarl J, Schnerch D, Lübbert M. BI-2536-targeting the mitotic kinase Polo-like kinase 1 (Plk1). Recent Results Cancer Res 2010; 184: 215-218.
22. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A et al. Polo-Like Kinase 1 (PLK1) inhibition kills glioblastoma multiforme brain tumour cells in part through loss of SOX2 and delays tumour progression in mice. Stem Cells 2012; 30: 1064-1075.
23. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009; 8: 3024-3035.
24. Shen T, Li Y, Yang L, Xu X, Liang F, Liang S et al. Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells. Int J Biochem Cell Biol 2012; 44: 423-429.
25. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 2011; 71: 3317-3327.
26. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S. Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005; 46: 225-231. (Pubitemid 40185952)
27. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997; 43: 7-14. (Pubitemid 27090862)
28. Mitchison T.J. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23: 1-6 2012.
29. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10: 265-275.
30. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010; 51: 857-868.
31. Rosario CO, Ko MA, Haffani YZ, Gladdy RA, Paderova J, Pollett A et al. Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proc Natl Acad Sci USA 2010; 107: 6888-6893.
32. Macmillan JC, Hudson JW, Bull S, Dennis JW, Swallow CJ. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol 2001; 8: 729-7402.
33. Soussi T. Handbook OF p53 Mutation in Cell Lines. Version 1.0 07/2007 http://p53.free.fr/Database/Cancer-cell-lines/cell-lines-1.0.pdf.
34. Guan R, Tapang P, Leverson JD, Giranda VL, Luo Y. Small interfering RNAmediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65: 2698-2704. (Pubitemid 40490070)
35. Renner AG, Dos Santos C, Recher C, Bailly C, Cré ancier L, Kruczynski A et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114: 659-662.
36. Oliveira JC, Brassesco MS, Pezuk JÁ , Morales AG, Valera ET, Montaldi AP et al. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol 2012; 11: 587-592.
37. Pezuk JA, Brassesco MS, Oliveira JC, Morales AG, Montaldi AP, Sakamoto-Hojo ET et al. Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells. Clin Exp Med 2013; 13: 75-80.
38. Morales AG, Brassesco MS, Pezuk JA, Morales AG, Montaldi AP, Sakamoto-Hojo ET et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 2011; 22: 995-1001.
39. Wolf S, Lorenz J, Mossner J, Wiedmann M. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol 2010; 16: 156-166.
40. Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G et al. Polo-like Kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res 2012; 73: 813-823.
41. Liu X, Choy E, Harmon D, Vincent-Salomon A, Tesson B, Rigaill G et al. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 2011; 22: 444-453.
42. Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr Biol 2007; 17: R280-R283. (Pubitemid 46566537)
43. Ianzini F, Mackey MA. Mitotic Catastrophe. In: Gewirtz DA, Holt SE (eds). Cancer Drug Discovery and Development Apoptosis, Senescence and Cancer. S Grant Humana Press: Totowa, NJ, USA, 2007.
44. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15: 1153-1162. (Pubitemid 351850968)
45. Yim H, Erikson RL. Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol 2009; 29: 2609-2621.
46. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 2011. doi:10.1016/urolonc.2011.11.028.
47. Han DP, Cui JT, Lu AG, Chen XH, Feng B, Zong YP et al. Influence of silencing Pololike kinase 1 on migration and invasion of colorectal cancer cells. Zhonghua Wei Chang Wai Ke Za Zhi 2011; 14: 61-64.
48. Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix 2007Cancer Res 67: 11106-11110.
49. Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B et al. A Phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 2013; 14: 19-27.
50. Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 2012; 19: e28-e35.
51. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network of Core Institutes (NOCI). Eur J Cancer 2010; 46: 2206-2215.
52. Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010; 5: 1060-1067.